India's $50B+ pharma market is the pharmacy of the world, supplying 20% of global generics. We help pharmaceutical and healthcare companies navigate API pollution, biomedical waste, water-intensive manufacturing, and drug access imperatives.
The most material ESG issues for pharmaceutical and healthcare companies under India's BRSR framework and global disclosure standards.
Active Pharmaceutical Ingredient production generates complex chemical effluents and air emissions, particularly in manufacturing clusters like Hyderabad and Baddi.
Hospitals, diagnostics labs, and manufacturing facilities generate hazardous biomedical waste requiring strict segregation, treatment, and disposal per CPCB rules.
Bulk drug manufacturing is highly water-intensive. Effluent containing pharmaceutical residues poses significant environmental and public health risks if inadequately treated.
As the world's generic drug supplier, Indian pharma faces unique expectations on drug pricing, accessibility for underserved populations, and equitable distribution.
Ethical conduct of clinical trials, informed consent, patient safety, and equitable access to trial outcomes are critical governance and social responsibility issues.
Pharmaceutical effluents containing antibiotic residues contribute to AMR, a global health crisis. Manufacturing discharge limits for antibiotics are under increasing regulatory scrutiny.
Chemical exposure, solvent handling, and cleanroom environments create occupational health risks requiring robust safety systems and health monitoring.
Complex global supply chains for APIs, intermediates, and excipients require rigorous quality, environmental, and social due diligence to prevent contamination and ensure compliance.
Structural complexities that make ESG transformation in the pharmaceutical and healthcare sector uniquely demanding in India.
Manufacturing clusters in Hyderabad, Baddi, and other hubs face severe water pollution from API production. Complex chemical effluents containing pharmaceutical residues, solvents, and heavy metals require advanced treatment beyond conventional ETPs.
Hyderabad & Baddi clusters under CPCB scrutinyIndia generates over 600 tonnes of biomedical waste daily. Inadequate segregation, limited Common Biomedical Waste Treatment Facility (CBWTF) capacity, and compliance gaps create environmental and public health risks across the healthcare value chain.
600+ tonnes/day of biomedical wasteBulk drug manufacturing consumes 200-500 KL of water per tonne of product. With many manufacturing sites in water-stressed regions, reducing freshwater dependency while maintaining GMP standards is a critical operational challenge.
200-500 KL water per tonne of bulk drugThe critical metrics that investors, regulators, and BRSR assessors evaluate for pharmaceutical and healthcare companies.
Chemical and Biological Oxygen Demand in treated effluent discharge. Primary measure of organic pollution load from pharmaceutical manufacturing.
Benchmark: COD <250 mg/L, BOD <30 mg/L (CPCB)Total water consumption normalised by revenue. Tracks efficiency of water use across manufacturing, cleaning, and cooling operations.
Benchmark: Declining YoY, ZLD targetPercentage of total waste (hazardous and non-hazardous) diverted from landfill through recycling, recovery, co-processing, or incineration with energy recovery.
Benchmark: >90% diversion from landfillConcentration of active pharmaceutical ingredients in treated effluent. Critical for AMR prevention and increasingly monitored by regulators globally.
Benchmark: Below PNEC thresholdsNumber of lost-time injuries per million hours worked. Critical for chemical handling environments with solvent, reagent, and cleanroom exposure risks.
Benchmark: <0.5 LTIFR (global best practice)Number of patients served through patient access programmes, tiered pricing, and donation initiatives. Key social impact metric for pharma companies.
Benchmark: Expanding reach YoYThe regulatory framework governing ESG obligations for India's pharmaceutical and healthcare sector spans environmental, social, and quality dimensions.
The Central Pollution Control Board sets strict discharge standards for pharmaceutical manufacturing including COD, BOD, TSS, and specific pharmaceutical residue limits. Common Effluent Treatment Plants (CETPs) in pharma clusters face enhanced monitoring requirements.
Comprehensive regulations mandate colour-coded segregation, authorised treatment, and bar-coded tracking of biomedical waste from hospitals, clinics, and manufacturing facilities. Annual reporting to SPCBs is mandatory with strict penalties for non-compliance.
Government's Production Linked Incentive scheme for bulk drug parks includes environmental sustainability requirements for new facilities. Parks must incorporate zero liquid discharge, common effluent treatment, and green building standards from inception.
The Drug Price Control Order regulates prices of essential medicines through the National Pharmaceutical Pricing Authority. Compliance with ceiling prices while maintaining quality and sustainability investments creates margin pressure for manufacturers.
For nutraceuticals and food-pharma crossover products, FSSAI quality and safety standards apply alongside pharmaceutical regulations, requiring dual compliance systems for companies operating across both segments.
SEBI's mandatory disclosure framework requires detailed reporting on environmental impact, worker safety, and product responsibility for listed pharma companies. Healthcare-specific metrics on drug access, clinical trial ethics, and waste management are key focus areas.
A structured methodology designed for the regulatory complexity and public health responsibility of India's pharmaceutical and healthcare sector.
Map pharma-specific materiality covering effluent quality, water intensity, biomedical waste, and drug access. Establish baselines and benchmark against Indian and global pharmaceutical peers.
Assess compliance across CPCB effluent norms, BMW Rules, hazardous waste regulations, and air emission standards. Identify gaps and prioritise remediation for manufacturing sites.
Develop water reduction roadmaps, ZLD implementation plans, solvent recovery optimisation, and waste-to-value pathways specific to pharmaceutical manufacturing processes.
Structure disclosures across all nine BRSR principles with pharma-appropriate metrics on environmental impact, worker safety, product responsibility, and community health programmes.
Develop anti-microbial resistance stewardship programmes, pharmaceutical residue monitoring systems, and drug access frameworks aligned with global best practice and Indian regulations.
Quarterly performance tracking, annual target recalibration, and investor-ready ESG communication to demonstrate measurable progress year over year.
Schedule a sector consultation to assess your environmental compliance, BRSR readiness, and sustainability strategy for pharmaceutical or healthcare operations.
Book Sector Consultation →